Alberta Precision Laboratories, Calgary, Alberta, Canada.
Department of Pathology and Laboratory Medicine, University of Calgarygrid.22072.35, Calgary, Alberta, Canada.
J Clin Microbiol. 2022 Jul 20;60(7):e0080721. doi: 10.1128/jcm.00807-21. Epub 2022 Apr 7.
Ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam are among the newest β-lactam/β-lactamase inhibitors (BL/BLIs) introduced to the North American antibiotic market. All have broad Gram-negative activity, including against certain carbapenemases. Despite this, susceptibility testing is warranted due to variable activity against certain β-lactamases (e.g., oxacillinases) and the presence of acquired resistance mechanisms in some isolates. Here, we discuss what we know about these new antimicrobial agents and how to navigate implementation of susceptibility testing and reporting of these agents in clinical laboratories.
头孢他啶-阿维巴坦、美罗培南-比阿培南和亚胺培南-雷利巴坦是北美抗生素市场推出的最新β-内酰胺/β-内酰胺酶抑制剂 (BL/BLIs) 之一。所有这些药物都对革兰氏阴性菌具有广泛的活性，包括某些碳青霉烯酶。尽管如此，由于对某些β-内酰胺酶（例如，氧头孢烯酶）的活性不同，以及某些分离株存在获得性耐药机制，仍需要进行药敏试验。在这里，我们讨论了我们对这些新的抗菌药物的了解，以及如何在临床实验室中进行药敏试验的实施和这些药物的报告。
